[
  {
    "ts": null,
    "headline": "Why the Market Dipped But Merck (MRK) Gained Today",
    "summary": "Merck (MRK) closed at $79.29 in the latest trading session, marking a +1.29% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=c6b1b09a28a67a7b1d761ae05b44c232472d53205abfdd5feb1110d25be17ad1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750283102,
      "headline": "Why the Market Dipped But Merck (MRK) Gained Today",
      "id": 135376678,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) closed at $79.29 in the latest trading session, marking a +1.29% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=c6b1b09a28a67a7b1d761ae05b44c232472d53205abfdd5feb1110d25be17ad1"
    }
  },
  {
    "ts": null,
    "headline": "Merck (NYSE:MRK) Begins Phase 3 Trial Of Innovative Prostate Cancer Treatment",
    "summary": "Merck (NYSE:MRK) recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic castration-resistant prostate cancer. Alongside this major development, the company saw FDA approval of KEYTRUDA for head and neck cancer, and embarked on a collaborative Phase 3 dengue vaccine trial, possibly contributing to its 2.92% stock price increase over the last month. In a market characterized by...",
    "url": "https://finnhub.io/api/news?id=7ab13545b2bfe251e48f102502ca16e3a6cbfa5a11f59d9de045db6631d2d3e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750268667,
      "headline": "Merck (NYSE:MRK) Begins Phase 3 Trial Of Innovative Prostate Cancer Treatment",
      "id": 135376679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic castration-resistant prostate cancer. Alongside this major development, the company saw FDA approval of KEYTRUDA for head and neck cancer, and embarked on a collaborative Phase 3 dengue vaccine trial, possibly contributing to its 2.92% stock price increase over the last month. In a market characterized by...",
      "url": "https://finnhub.io/api/news?id=7ab13545b2bfe251e48f102502ca16e3a6cbfa5a11f59d9de045db6631d2d3e8"
    }
  },
  {
    "ts": null,
    "headline": "Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward",
    "summary": "Phase 1 data for Spyre Therapeutics, Inc.'s SPY002 & SPY072 show promise in autoimmune treatments. Advancing to Phase 2 trials. Click for my updated look at SYRE.",
    "url": "https://finnhub.io/api/news?id=509f99c2dec51e2d52cc8e5d1fb62285a3fe661bbb65fa68bbcaaf4af7243c56",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750258683,
      "headline": "Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward",
      "id": 135373191,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205530499/image_2205530499.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Phase 1 data for Spyre Therapeutics, Inc.'s SPY002 & SPY072 show promise in autoimmune treatments. Advancing to Phase 2 trials. Click for my updated look at SYRE.",
      "url": "https://finnhub.io/api/news?id=509f99c2dec51e2d52cc8e5d1fb62285a3fe661bbb65fa68bbcaaf4af7243c56"
    }
  },
  {
    "ts": null,
    "headline": "IHE: Healthcare Dashboard For June",
    "summary": "This is our monthly dashboard series on Healthcare and Pharma stocks. Read the full analysis here, and which 10 healthcare stocks were cheaper than their peers in June 2025.",
    "url": "https://finnhub.io/api/news?id=5bd3d37037c925aa23d9d9138ebe7c3a09ec14b7fca953591a7be9042018cd10",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750253083,
      "headline": "IHE: Healthcare Dashboard For June",
      "id": 135370933,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/901284104/image_901284104.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "This is our monthly dashboard series on Healthcare and Pharma stocks. Read the full analysis here, and which 10 healthcare stocks were cheaper than their peers in June 2025.",
      "url": "https://finnhub.io/api/news?id=5bd3d37037c925aa23d9d9138ebe7c3a09ec14b7fca953591a7be9042018cd10"
    }
  },
  {
    "ts": null,
    "headline": "American Kidney Fund Launches Kidney Cancer Education Campaign",
    "summary": "ROCKVILLE, Md., June 18, 2025 (GLOBE NEWSWIRE) -- Ahead of World Kidney Cancer Day on June 19, the American Kidney Fund (AKF) today announced a new educational campaign on renal (kidney) cancer. With support from Merck, this campaign will provide people with kidney cancer and their families and caregivers easy-to-understand information and support. Kidney cancer accounts for 4% of all cancers, according to the National Cancer Institute (NCI). About 80,000 people are diagnosed with some type of k",
    "url": "https://finnhub.io/api/news?id=c706ea686fb570762676125f71b137df55f3df9f4b1e2ff78722220eec318462",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750252380,
      "headline": "American Kidney Fund Launches Kidney Cancer Education Campaign",
      "id": 135362702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "ROCKVILLE, Md., June 18, 2025 (GLOBE NEWSWIRE) -- Ahead of World Kidney Cancer Day on June 19, the American Kidney Fund (AKF) today announced a new educational campaign on renal (kidney) cancer. With support from Merck, this campaign will provide people with kidney cancer and their families and caregivers easy-to-understand information and support. Kidney cancer accounts for 4% of all cancers, according to the National Cancer Institute (NCI). About 80,000 people are diagnosed with some type of k",
      "url": "https://finnhub.io/api/news?id=c706ea686fb570762676125f71b137df55f3df9f4b1e2ff78722220eec318462"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded.",
    "summary": "Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded.",
    "url": "https://finnhub.io/api/news?id=55b9eef8f996ebd3ba719b8233dc6e060a94b8effa616b86e912572305850c68",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750250760,
      "headline": "Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded.",
      "id": 135390390,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded.",
      "url": "https://finnhub.io/api/news?id=55b9eef8f996ebd3ba719b8233dc6e060a94b8effa616b86e912572305850c68"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy's new US vaccine panel to discuss measles shot for children",
    "summary": "A new panel of U.S. vaccine advisersappointed by Health Secretary Robert F. Kennedy Jr. will vote onflu shots that contain a mercury-based preservative calledthimerosal and discuss recommendations...",
    "url": "https://finnhub.io/api/news?id=681bb90aef7060dbc3db952758c6091b5adf6a5751a32239c326ab51267e6fbb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750246456,
      "headline": "Kennedy's new US vaccine panel to discuss measles shot for children",
      "id": 135362730,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "A new panel of U.S. vaccine advisersappointed by Health Secretary Robert F. Kennedy Jr. will vote onflu shots that contain a mercury-based preservative calledthimerosal and discuss recommendations...",
      "url": "https://finnhub.io/api/news?id=681bb90aef7060dbc3db952758c6091b5adf6a5751a32239c326ab51267e6fbb"
    }
  },
  {
    "ts": null,
    "headline": "CDC's vaccine advisory committee to vote on RSV, flu shots",
    "summary": "The U.S. Centers for Disease Controland Prevention panel of vaccine experts will vote on shots forrespiratory syncytial virus and influenza at a meeting scheduledfor June 25 and 26, according to...",
    "url": "https://finnhub.io/api/news?id=6153cb5ab495762c37fc865f0e03b6b417679f0aee4e925f62cb76dc20f15909",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750245383,
      "headline": "CDC's vaccine advisory committee to vote on RSV, flu shots",
      "id": 135361267,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "The U.S. Centers for Disease Controland Prevention panel of vaccine experts will vote on shots forrespiratory syncytial virus and influenza at a meeting scheduledfor June 25 and 26, according to...",
      "url": "https://finnhub.io/api/news?id=6153cb5ab495762c37fc865f0e03b6b417679f0aee4e925f62cb76dc20f15909"
    }
  },
  {
    "ts": null,
    "headline": "IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer",
    "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., June 18, 2025--The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor.",
    "url": "https://finnhub.io/api/news?id=ed69f13b93eff18b373de9dac4c68ce4166656976903476a25edecaced74d4f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750244400,
      "headline": "IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer",
      "id": 135362704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., June 18, 2025--The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor.",
      "url": "https://finnhub.io/api/news?id=ed69f13b93eff18b373de9dac4c68ce4166656976903476a25edecaced74d4f3"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Phase 3 trial in prostate cancer",
    "summary": "Merck and Daiichi Sankyo announce that the first patient has been treated in a Phase 3 trial for prostate cancer to evaluate the efficacy and safety of ifinatamab deruxtecan compared to docetaxel in...",
    "url": "https://finnhub.io/api/news?id=de192c99e42a5af900afd65e9758e493c4177b16670d3a1e833ff788c8b18f37",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750240696,
      "headline": "Merck: Phase 3 trial in prostate cancer",
      "id": 135355723,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck and Daiichi Sankyo announce that the first patient has been treated in a Phase 3 trial for prostate cancer to evaluate the efficacy and safety of ifinatamab deruxtecan compared to docetaxel in...",
      "url": "https://finnhub.io/api/news?id=de192c99e42a5af900afd65e9758e493c4177b16670d3a1e833ff788c8b18f37"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Growth Remains a Key Priority for Merck",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of Best Dividend Stocks to Buy for Dependable Growth. Merck & Co., Inc. (NYSE:MRK) is one of the best dividend stocks for dependable dividend growth. The company is not only recognized for its strong pipeline but also for its consistent dividend growth. It expects approvals for up to […]",
    "url": "https://finnhub.io/api/news?id=aa1842cdbc9d884b647c3f85324877472d5aec0271210b2beb28c3da5d132758",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750230711,
      "headline": "Dividend Growth Remains a Key Priority for Merck",
      "id": 135349525,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of Best Dividend Stocks to Buy for Dependable Growth. Merck & Co., Inc. (NYSE:MRK) is one of the best dividend stocks for dependable dividend growth. The company is not only recognized for its strong pipeline but also for its consistent dividend growth. It expects approvals for up to […]",
      "url": "https://finnhub.io/api/news?id=aa1842cdbc9d884b647c3f85324877472d5aec0271210b2beb28c3da5d132758"
    }
  }
]